Latest Regulatory News

Medallion Metals and IGO Limited have agreed to extend the deadline for completing the Forrestania Nickel Operation acquisition, allowing more time to meet key conditions and secure environmental approvals.

Mayne Pharma has rejected Cosette Pharmaceuticals’ notice to terminate their merger agreement, citing Cosette’s failure to meet obligations that led to regulatory approval issues. The dispute raises fresh uncertainty over the proposed acquisition’s future.

Orion Minerals has responded to an ASX price query following a recent uptick in its share price, confirming no undisclosed material information exists while highlighting ongoing financing talks with Glencore.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

LTR Pharma has received regulatory clearance from the Therapeutic Goods Administration to commence its Phase II clinical trial of SPONTAN, focusing on men aged 65 and over. Patient recruitment is set to begin early next year, aiming to address a key gap in erectile dysfunction treatment.

Charter Hall Group is set to execute a capital reallocation of 42.28 cents per security, shifting capital from its limited company shares to property trust units without cash exchanges. This move, approved by securityholders, carries important tax implications for investors.

Terrain Minerals has completed a $1.42 million placement in December, topping up an earlier October raise to fully fund its upcoming drilling campaigns and maiden JORC resource estimate.

Pacific Lime and Cement Limited has formalised a pivotal Project Development Agreement with the Papua New Guinea government, marking a major step forward for its Central Lime and Cement Project and signalling strong sovereign support.

Immuron Limited reports topline results from a Uniformed Services University trial of a third-party ETEC product that missed its primary endpoint, reaffirming commitment to its established Travelan dosing ahead of FDA discussions.

TPG Telecom has successfully completed its Retail Reinvestment Plan, raising $73 million and increasing its free float to 27%, as part of a broader $373 million capital raise aimed at debt reduction.

Jatcorp Limited has announced a fully underwritten pro-rata rights issue to raise approximately $4.2 million, aiming to strengthen working capital and accelerate growth in China and Southeast Asia. Eligible shareholders can subscribe at $0.15 per share with an option for additional shares under a Top-Up Facility.

Ampol Limited reports solid first-half 2025 results, highlights a strengthening refinery margin, and advances its strategic acquisition of EG Australia, aiming to reshape its retail footprint and cost base.